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1University of Latvia, Riga, Latvia; 2P. Stradins University Hospital, Riga,
Latvia
OBJECTIVES: Noncompliance to immunosuppressive medica-
tion regimens in renal transplant recipients is an important factor
affecting graft survival. The objective of our study was to
examine the prevalence of noncompliance, to verify factors asso-
ciated with this condition as well as to assess the long term
impact of noncompliance on graft survival after renal trans-
plantation in Latvia. METHODS: Noncompliance with medica-
tion and follow-up care was retrospectively evaluated in 311
adult renal transplant recipients (mean age 48.7 ± 14.4 years,
48.2% female, 86.8% primary graft) with at least a 5 year
follow-up period, using self-report questionnaires, clinician
rating, 20% rate of missing outpatient visits and measurement
of the amount of medication that remained unused (on account
of pharmacists’ report of non-received pills). Thus, our patient
compliance data included considerations of natural environment.
Long-term graft and patient outcomes in compliant and non-
compliant patients were acute rejection rate and chronic allograft
dysfunction, graft and patient one, three and ﬁve year survival.
RESULTS: The prevalence of immunosuppressive medication
regimen noncompliance in this patient setting was 6.1% and
prevalence of appointment noncompliance was 7.1%. Noncom-
pliant patients had more acute rejection episodes (P < 0.05) and
chronic allograft dysfunction (P = 0.02). Risk of all cause graft
failure in the noncompliant group was higher—OR 9.3 (95% CI
3.0–28.8; P < 0.001) compared to the compliant group. Graft
survival at one, three and ﬁve years was 88.3%, 81.3% and
75.7%, respectively, for compliant patients and 73.7%, 61.4%
and 37.9% respectively for noncompliant patients (Log Rank
5.09; P = 0.02). The risk factors associated with noncompliance
was younger age (P < 0.05) and a immunosuppressive regimen
with the highest number of pills (P = 0.02. CONCLUSIONS:
Patients’ compliance with medication and follow-up care after
renal transplantation shows long-term clinical beneﬁts. Thus, it
is of utmost importance to develop intervention strategies to
enhance compliance in this population.
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BUDGET IMPACT ANALYSIS OF MIMPARA AMONG DIALYSIS
PATIENTS IN BELGIUM USING A MARKOV SIMULATION
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OBJECTIVE: To demonstrate the impact of Mimpara (MIM), a
drug against secondary hyperparathyroidism (sHPT), on the
dialysis health care budget in Belgium over time. METHODS: A
Markov model was developed to compare cost of dialysis
patients on standard treatment of care (SOC) with patients on
MIM + SOC (add-on model). The model operates in 1/2 year
cycles over 5 years starting with a cohort of 5,400 patients
(prevalence data). Each year new cases were added to the cohort
and a % dropped out due to death or renal transplant. Mortal-
ity risk was calculated from 2-year cohort dialysis database
(CDB) (n = 13,000)1. Patient distributions for sHPT, calcium x
phosphor values, and MIM dosages were taken from phase III
trials for the MIM arm and from the 2-year CDB for the SOC
arm. Patients withdrawing from MIM were treated as SOC
patients. According to CDB 35% of the initial cohort may
receive MIM (= % of sHPT). Drug uptake was 30% in ﬁrst cycle
with 20% increase per added cycle. MIM drug costs were
€3109/year in ﬁrst cycle and €2617/year per added cycle as only
drug responders (85%) remained on study drug. Other treatment
costs were taken from a retrospective cost study in Belgium2
using average daily cost of €214 per dialysis patient, plus €50/day
for sHPT. Annual 3% discount rate was applied. RESULTS:
Cumulative 5-year cost difference of €7.4 million was seen
between SOC- and MIM-arm (<0.4% total cost increase with
MIM). Running the analysis per year, cost savings early in MIM-
treatment were observed due to reduction in treatment costs of
morbidities related to shift from sHPT. Slight increase in treat-
ment costs was seen later on due to observed survival beneﬁt
with MIM. CONCLUSION: Major budget shifts will not be seen
with Mimpara in its approved indication.
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ECONOMIC EVALUATION OF EVEROLIMUS WITH REDUCED-
DOSE CYCLOSPORINE IN DE NOVO RENAL TRANSPLANT
RECIPIENTS IN HUNGARY
Kósa J1,Yang X2, Kiss É1, Kaló Z1
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Basel, Switzerland
OBJECTIVE: The objective of this study was to assess the eco-
nomic impact of everolimus with reduced-dose CsA in de novo
renal transplant recipients in the Hungarian health care setting.
METHODS: Analyses of the trial RADB201 found that total
direct medical costs (costs without everolimus, CsA and MMF)
are mostly dependent on key clinical events, i.e., number of days
on dialysis (hemo- and peritoneal), inpatient length of stay (LOS)
due to adverse events (AE) or infection (INF), and episodes of
biopsy proven acute rejection (BPAR). A multivariate regression
model was applied on the RADB-201 database to predict total
direct medical costs based on these clinical events. The obtained
coefﬁcients, adjusted for patient characteristics, were applied to
the clinical data of the RADA-2306 trial, hence predicting the
economic consequences of the reduced CsA dose . We applied
Hungarian unit costs to the entire clinical database. The time
horizon of the analysis was one year. RESULTS: The model pre-
dicted that the incremental cost for one day on hemodialysis and
peritoneal dialysis was HF 134,617 and HF 50,149, one day of
hospitalization due to AE and INF was HF 41,685 and HF
45,231 and the one BPAR event reached HF 523,907, all these
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